Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option
Y Ren, JM Miao, YY Wang, Z Fan, XB Kong… - Frontiers in …, 2022 - frontiersin.org
Immunotherapy is one of the promising strategies in the treatment of oncology. Immune
checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical …
checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical …
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …
Novel WRN helicase inhibitors selectively target microsatellite-unstable cancer cells
Microsatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due
to expanded DNA (TA) n dinucleotide repeats. WRN is a promising synthetic lethal target for …
to expanded DNA (TA) n dinucleotide repeats. WRN is a promising synthetic lethal target for …
Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort
Background Aging is an important risk factor for most chronic diseases. Patients with COPD
develop more comorbidities than non-COPD subjects. We hypothesized that the …
develop more comorbidities than non-COPD subjects. We hypothesized that the …
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive
characterization of T cell diversity may be key to understanding the success of …
characterization of T cell diversity may be key to understanding the success of …
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic …
Background Immune checkpoint inhibitors (ICIs) are highly effective in patients with
microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer …
microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer …
Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer
S Li, R Na, X Li, Y Zhang, T Zheng - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Although immune checkpoint inhibitors (ICIs) have gained much attention in managing
cancer, only a minority of patients, especially those with tumors that have been classified as …
cancer, only a minority of patients, especially those with tumors that have been classified as …
Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody
L Zhang, Z Geng, B Hao, Q Geng - Cancer Control, 2022 - journals.sagepub.com
Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G
4 antibody developed by BeiGene. The structure of tislelizumab has been modified to …
4 antibody developed by BeiGene. The structure of tislelizumab has been modified to …
Gut microbiome: decision-makers in the microenvironment of colorectal cancer
Colorectal cancer (CRC) is a common malignancy of the gastrointestinal tract, accounting for
the second most common cause of gastrointestinal tumors. As one of the intestinal barriers …
the second most common cause of gastrointestinal tumors. As one of the intestinal barriers …